Novartis AG (NOVN.SW) CHF120.20 after-hours 09 Feb 2026: most-active stock insight

NOVN.SW stock opened the after-hours session on 09 Feb 2026 at CHF120.20, trading as one of the most-active Swiss healthcare names on the SIX. Volume reached 3,339,717 shares, above the 3-month average of 3,094,948, and the price sits near the 52-week high of CHF120.64. Traders are watching fundamentals — EPS CHF5.55 and P/E 21.61 — alongside technicals showing short-term strength. Meyka AI’s real-time system flagged the move as high-activity, linking news flow and sector momentum to the stock’s intraday gains

NOVN.SW stock: price, volume and session context

Novartis AG (NOVN.SW) closed the regular session at CHF119.28 and is trading after-hours at CHF120.20 on 09 Feb 2026. The daily range was CHF119.74–CHF121.40 with volume 3,339,717, giving a relative volume of 1.06 versus average. The move keeps NOVN.SW stock near its 52-week high CHF120.64, which helps explain higher participation in the most-active list on the SIX

NOVN.SW stock: fundamentals and valuation

Key metrics for NOVN.SW stock: Market cap CHF228.90B, EPS CHF5.55, P/E 21.61, Price/ sales 5.21, and dividend yield 2.92% (dividend per share CHF4.51). Price averages show a bullish trend: 50-day CHF111.21 and 200-day CHF101.55. These ratios point to a premium valuation versus some peers but solid cash generation: free cash flow yield stands near 5.68%, supporting the dividend and buyback capacity

NOVN.SW stock: technical picture and trading signals

Technicals show strength for NOVN.SW stock. RSI 74.23 (overbought) and MACD histogram +0.53 suggest momentum is positive but extended. Bollinger middle band is CHF108.81, and ATR is CHF1.69, implying measured intraday volatility. Traders should note the stock is in a short-term overbought band while ADX 22.67 indicates a moderate trend; volume confirmation keeps the move credible

NOVN.SW stock: growth drivers and risks

Novartis’s Innovative Medicines pipeline and Sandoz generics business drive revenue diversification for NOVN.SW stock. Partnerships, including inclisiran work with Alnylam, and oncology collaborations add upside. Key risks include pricing pressure in generics, regulatory setbacks, and Sandoz margin volatility. Financial growth metrics show revenue growth 10.85% (FY 2024) but net income contraction of -19.59%, so investors must weigh near-term profit swings against long-term pipeline value

NOVN.SW stock: sector context and comparable performance

Healthcare on the SIX has delivered 3-month +13.79% and 1-year +3.20% performance; Novartis sits among sector leaders with 1-year +22.77% for the stock (per historical returns). Peer comparisons show Roche and Abbott with similar P/E bands; NOVN.SW stock’s higher free cash flow yield and ROE 34.31% support a premium rating within the drug-manufacturer group

Meyka AI rates NOVN.SW with a score out of 100 and technical grade

Meyka AI rates NOVN.SW with a score out of 100: Score 77.95 | Grade B+ | Suggestion: BUY. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Technical indicators (RSI and MACD) and above-average volume lift the near-term signal, while valuation metrics temper enthusiasm. These grades are informational only and not investment advice

Final Thoughts

Novartis AG (NOVN.SW) is one of the most-active Swiss healthcare stocks after-hours on 09 Feb 2026, trading at CHF120.20 with volume 3,339,717 that exceeds the average. The firm shows solid cash generation, EPS CHF5.55, and a P/E of 21.61, while technicals point to short-term overbought conditions. Meyka AI’s forecast model projects short-term and multi-year scenarios: monthly CHF123.14 (+2.45%), yearly CHF108.32 (-9.88%), and 5-year CHF133.35 (+10.94%) relative to the current price. For risk-managed exposure we suggest a conservative price target range: CHF110.00 (downside -8.48%), base CHF130.00 (+8.15%), and bull CHF150.00 (+24.79%). Investors should balance pipeline upside and dividend yield 2.92% against generics margin risk and regulatory headlines. Meyka AI, as an AI-powered market analysis platform, flags NOVN.SW stock for active monitoring but emphasizes that forecasts are model-based projections and not guarantees

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.